Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015)

Abstract

Activities of tedizolid and comparators were evaluated against gram-positive isolates responsible for skin and skin structure infections, pneumonia, and bloodstream infections. Non-duplicate gram-positive isolates (8011) were collected from 20 European countries/regions. Tedizolid (0.12\u2009mg/L) showed similar results of minimum inhibitory concentration required to inhibit the growth of 50% of organisms (MIC50) regardless of pathogen/group or infection type, except for coagulase-negative staphylococci, Enterococcus faecalis, and viridans group streptococci (VGS), against which tedizolid had MIC50 values of 0.06, 0.25, and 0.06\u2009mg/L, respectively. Similar results of tedizolid MIC50 and minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC90) (MIC50/90, 0.12/0.12\u2009mg/L) were obtained against methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Tedizolid, linezolid, and daptomycin were active against enterococci. Tedizolid (MIC90, 0.12–0.25\u2009mg/L), ceftaroline (MIC90, 0.12\u2009mg/L), and vancomycin (MIC90, 0.25–0.5\u2009mg/L) had the lowest MIC90 values against Streptococcus pneumoniae and VGS, whereas ceftaroline (MIC90, ≤0.015\u2009mg/L), penicillin (MIC90, ≤0.06\u2009mg/L), ceftriaxone (MIC90, ≤0.06–0.12\u2009mg/L), and tedizolid (MIC90, 0.12\u2009mg/L) were the most potent against β-haemolytic streptococci. Tedizolid displayed potent activity against gram-positive isolates from Europe, regardless of infection type.